A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types

NCT02296879 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Young Suk Park